Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q1 2025 · 10-Q
Revenue$11.52M$11.52M+13.1% vs Q1 2024 Net Income$1.65M$1.65M+132.6% vs Q1 2024 EPS Diluted$0.06$0.06−62.5% vs Q1 2024 Gross Profit$7,370,000+16.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flow$1,235,000N/M Margins · derivedGross margin64.0%+2.0 pt vs Q1 2024
Operating margin15.9%+4.9 pt vs Q1 2024
Net margin14.3%+7.3 pt vs Q1 2024
ended Mar 31, 2025 · filed May 8, 2025 · 38 d after period end